Ignite Creation Date:
2025-12-18 @ 8:10 AM
Ignite Modification Date:
2025-12-23 @ 9:57 PM
Study NCT ID:
NCT03305224
Status:
None
Last Update Posted:
2021-09-09 00:00:00
First Post:
2017-08-28 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
The Combination Therapy With Ra-223 and Enzalutamide
Sponsor:
None
Organization:
Study Overview
Official Title:
The Study of Combination Therapy With Radium-223 and Enzalutamide in Osaka City University
Status:
None
Status Verified Date:
2021-09
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CORE-OCU
Brief Summary:
This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: